Doxofylline

	WikiDoc Resources for Doxofylline
Articles
Most recent articles on Doxofylline Most cited articles on Doxofylline Review articles on Doxofylline Articles on Doxofylline in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Doxofylline Images of Doxofylline Photos of Doxofylline Podcasts & MP3s on Doxofylline Videos on Doxofylline
Evidence Based Medicine
Cochrane Collaboration on Doxofylline Bandolier on Doxofylline TRIP on Doxofylline
Clinical Trials
Ongoing Trials on Doxofylline at Clinical Trials.gov Trial results on Doxofylline Clinical Trials on Doxofylline at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Doxofylline NICE Guidance on Doxofylline NHS PRODIGY Guidance FDA on Doxofylline CDC on Doxofylline
Books
Books on Doxofylline
News
Doxofylline in the news Be alerted to news on Doxofylline News trends on Doxofylline
Commentary
Blogs on Doxofylline
Definitions
Definitions of Doxofylline
Patient Resources / Community
Patient resources on Doxofylline Discussion groups on Doxofylline Patient Handouts on Doxofylline Directions to Hospitals Treating Doxofylline Risk calculators and risk factors for Doxofylline
Healthcare Provider Resources
Symptoms of Doxofylline Causes & Risk Factors for Doxofylline Diagnostic studies for Doxofylline Treatment of Doxofylline
Continuing Medical Education (CME)
CME Programs on Doxofylline
International
Doxofylline en Espanol Doxofylline en Francais
Business
Doxofylline in the Marketplace Patents on Doxofylline
Experimental / Informatics
List of terms related to Doxofylline

Doxofylline
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	R03DA11 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name 7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione;
CAS Number	69975-86-6 ;
PubChem CID	50942;
UNII	MPM23GMO7Z;
KEGG	D03898 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C11H14N4O4
Molar mass	266.25 g/mol
3D model (JSmol)	Interactive image;
	SMILES CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3;
(verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Doxofylline (INN), (also known as doxophylline) is a xanthine derivative drug used in the treatment of asthma.^[1]

It has antitussive^{[citation needed]} and bronchodilator^[2] effects, and acts as a phosphodiesterase inhibitor.^[3]

In animal and human studies, it has shown similar efficacy to theophylline but with significantly fewer side effects.^[4]

Unlike other xanthines, doxofylline lacks any significant affinity for adenosine receptors and does not produce stimulant effects. This suggests that its antiasthmatic effects are mediated by another mechanism, perhaps its actions on phosphodiesterase.^[1]

References

↑ ^1.0 ^1.1 Cirillo R, Barone D, Franzone JS (1988). "Doxofylline, an antiasthmatic drug lacking affinity for adenosine receptors". Arch Int Pharmacodyn Ther. 295: 221–37. PMID 3245738.
↑ Poggi R, Brandolese R, Bernasconi M, Manzin E, Rossi A (October 1989). "Doxofylline and respiratory mechanics. Short-term effects in mechanically ventilated patients with airflow obstruction and respiratory failure". Chest. 96 (4): 772–8. doi:10.1378/chest.96.4.772. PMID 2791671.
↑ Dini FL, Cogo R (2001). "Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects". Curr Med Res Opin. 16 (4): 258–68. doi:10.1185/030079901750120196. PMID 11268710.
↑ Sankar J, Lodha R, Kabra SK (March 2008). "Doxofylline: The next generation methylxanthine". Indian J Pediatr. 75 (3): 251–4. doi:10.1007/s12098-008-0054-1. PMID 18376093.

Dali Shukla, Subhashis Chakraborty, Sanjay Singh & Brahmeshwar Mishra. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy. 2009; 10(14): 2343-2356, DOI 10.1517/14656560903200667, PMID 19678793

Template:Asthma and copd rx Template:Phosphodiesterase inhibitors

[pmid3245738-1] 1.0 ^1.1 Cirillo R, Barone D, Franzone JS (1988). "Doxofylline, an antiasthmatic drug lacking affinity for adenosine receptors". Arch Int Pharmacodyn Ther. 295: 221–37. PMID 3245738.

[pmid2791671-2] Poggi R, Brandolese R, Bernasconi M, Manzin E, Rossi A (October 1989). "Doxofylline and respiratory mechanics. Short-term effects in mechanically ventilated patients with airflow obstruction and respiratory failure". Chest. 96 (4): 772–8. doi:10.1378/chest.96.4.772. PMID 2791671.

[pmid11268710-3] Dini FL, Cogo R (2001). "Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects". Curr Med Res Opin. 16 (4): 258–68. doi:10.1185/030079901750120196. PMID 11268710.

[4] Sankar J, Lodha R, Kabra SK (March 2008). "Doxofylline: The next generation methylxanthine". Indian J Pediatr. 75 (3): 251–4. doi:10.1007/s12098-008-0054-1. PMID 18376093.

[1]

[2]

[3]

[4]

Clinical data

AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	R03DA11 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name 7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione
CAS Number	69975-86-6^Y
PubChem CID	50942
UNII	MPM23GMO7Z
KEGG	D03898^Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₁H₁₄N₄O₄
Molar mass	266.25 g/mol
3D model (JSmol)	Interactive image
SMILES CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3
(verify)

Doxofylline

Overview

References

Navigation menu